KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Receivables (2019 - 2025)

Historic Change in Receivables for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $14.7 million.

  • GoodRx Holdings' Change in Receivables rose 14749.93% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.9 million, marking a year-over-year increase of 65525.53%. This contributed to the annual value of $2.3 million for FY2024, which is 9121.17% down from last year.
  • Per GoodRx Holdings' latest filing, its Change in Receivables stood at $14.7 million for Q3 2025, which was up 14749.93% from $28.9 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' Change in Receivables ranged from a high of $28.9 million in Q2 2025 and a low of -$31.0 million during Q3 2024
  • Moreover, its 5-year median value for Change in Receivables was $6.9 million (2023), whereas its average is $6.8 million.
  • Per our database at Business Quant, GoodRx Holdings' Change in Receivables skyrocketed by 408436.36% in 2021 and then tumbled by 128758.96% in 2024.
  • GoodRx Holdings' Change in Receivables (Quarter) stood at $19.6 million in 2021, then crashed by 119.14% to -$3.7 million in 2022, then soared by 699.79% to $22.5 million in 2023, then plummeted by 32.64% to $15.1 million in 2024, then fell by 2.78% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $28.9 million for Q2 2025, and $14.2 million during Q1 2025.